J&J's Application to Extend Patent on Anti-Tuberculosis Drug Bedaquiline Rejected

The patent would have extended J&J's monopoly on the anti-TB drug in India. But with this judgment, generic manufacturers can now make their own versions at an affordable price from this year.

Related Keywords

India ,New Delhi ,Delhi ,South Africa ,Phumeza Tisile ,Timesreported Latika Dawara ,Nandita Venkatesan ,Indian Patent Office On ,Indian Patent Office ,Economic Timesreported Latika Dawara ,Patents Act ,Bedaquiline ,Generic Drugs ,India Tuberculosis ,India Tuberculosis Treatment ,J Amp ,Latest Headlines ,Latest News ,Tb Drug ,Tb Drugs Cost ,